Keeping the Plan Working
Lisa Zahakos, RPA-C · Authorized synthetic narration

For our last case, Teresa is going home with a changed treatment plan.

Teresa is home after a hospitalization for worsening heart failure. Her discharge list includes medication changes. A cardiology visit is planned, but she does not know who will review her next blood test.

Clinical context. Confirmed heart failure with preserved ejection fraction; left ventricular ejection fraction 55 percent; chronic kidney disease and type 2 diabetes.

At the stable follow-up. E G F R 42 milliliters per minute per one point seven three square meters; potassium 4.7 milliequivalents per liter.

Current task. Reconcile therapy and assess eligibility and safety before adding a mineralocorticoid receptor antagonist.

Coordination gap. Laboratory date and responsible result reviewer are not documented.

Reconstruct what is happening at home.

Ask Teresa to bring the medicines she is actually taking, or review them by a reliable remote method. Compare the hospital list, the outpatient record, pharmacy information when available and her account. Resolve duplicate therapies, stopped medicines that remain in the record and prescriptions that were never filled. Ask about supplements, salt substitutes and nonprescription agents as part of the safety review.

Do not interpret a missed dose as lack of interest without asking why. Cost, transportation, language, vision, manual dexterity and unclear instructions may all affect the plan. If the medicine is unaffordable, record the barrier and the action needed to address it. A plan that depends on a nonexistent supply is not an implemented treatment.

Review symptoms, volume status, blood pressure and the trajectory of kidney function. The decision to add treatment must consider stability and the existing regimen. This fictional stable follow-up is an opportunity to close the monitoring gap; it is not permission to initiate therapy in a patient with acute deterioration without reassessment.

Use the heart-failure label, not a remembered kidney schedule.

Finerenone’s current US labeling includes adults with heart failure and left ventricular ejection fraction of at least 40 percent. Baseline potassium and E G F R are required. Do not initiate when potassium is above 5.0 milliequivalents per liter; initiation below E G F R 25 milliliters per minute per one point seven three square meters is not recommended. Strong C Y P 3 A 4 inhibitors and adrenal insufficiency are contraindications. Review interactions and the entire regimen.

For the heart failure indication, starting and target doses depend on baseline E G F R, with subsequent decisions guided by potassium and kidney function. At Teresa’s stated baseline E G F R of 42, the label’s starting dose is 10 milligrams daily and target is 20 milligrams daily, subject to subsequent laboratory results and tolerability. Do not replace the heart failure dosing table with the chronic kidney disease-with-diabetes table.

The heart failure label calls for potassium and E G F R four weeks after initiation and four weeks after dose adjustment, then periodically. Clinical changes may require earlier assessment. Use the current label for exact hold, restart and adjustment rules. The course does not replace those tables or a clinician’s judgment.

Here is the decision. Teresa’s potassium is 4.7 and E G F R 42. After other eligibility and interaction checks, what completes a finerenone initiation plan?

Pause here if you would like a moment to think it through.

The best next step in this case is: Use the heart failure dosing instructions, arrange four-week potassium/E G F R testing, and name the reviewer and patient-contact process.

The dose, tests, owner and communication process belong together.

A laboratory order needs an owner.

'Repeat labs' is not a complete plan. Specify the tests, date, location and responsible reviewer. The reviewer needs a process for acting on abnormal values and contacting Teresa. The team also needs a way to detect a test that was not completed; a missing result is not a normal result.

For this case, the plan could read: 'Basic metabolic panel at four weeks after initiation, with potassium and E G F R review by the prescribing clinician; earlier clinical assessment if symptoms or intercurrent illness warrant. Nurse care coordinator checks completion and contacts the prescriber for missing or abnormal results. Results and instructions communicated to Teresa and documented.' The local team must assign real names and workable escalation thresholds.

Confirm that the testing site is reachable and the order can be used there. Give Teresa a short written summary of when to go and whom to call. With her permission, include a support person. If a dose changes, the laboratory date must change with it; otherwise the chart can appear complete while the relevant monitoring is missed.

Record that the result was reviewed and the patient informed. Sending a message into a portal that Teresa does not use may not complete the loop. Ask which contact method works for her and follow the organization’s privacy and communication policies.

Explain benefit and risk in the same conversation.

Teresa asks, 'Will this medicine keep me out of the hospital?' A useful answer respects both evidence and uncertainty: 'In a large trial, this treatment reduced the combined rate of worsening heart-failure events and cardiovascular death. It cannot promise that you will never need hospital care. We also need to watch potassium and kidney function.'

Use the relevant population and endpoint when explaining a result. FINEARTS H F included mildly reduced and preserved ejection fraction; it counted recurrent worsening-heart failure events as well as cardiovascular death. A rate ratio for total events is not an individual patient’s chance of avoiding every event. The trial’s lack of a significant cardiovascular-death result alone should not be hidden.

Ask Teresa to explain why the blood test matters. If she says it is only to see whether the drug is working, clarify the safety purpose. Hyperkalemia may not announce itself with a clear symptom. Monitoring is part of the treatment, even when she feels well.

Do not let the routine pathway absorb an emergency.

Now change the vignette. Teresa calls with new breathlessness at rest and chest pressure. This is a different decision from arranging the next routine blood test. Arrange emergency assessment; in the United States, severe or potentially life-threatening symptoms warrant calling 911. Do not ask her to wait for the scheduled visit or simply repeat an outpatient laboratory test.

For nonemergency worsening symptoms, the care plan should explain how to reach the clinical team and when same-day advice is needed. Any individualized weight or symptom action plan should be provided by the treating team. Do not invent a universal diuretic self-adjustment rule from this case.

Use teach-back while she is stable: 'If you develop chest pressure and cannot catch your breath at rest, what will you do?' Then ask whom she contacts for a nonemergency concern and when her next test and visit occur. Correct the plan in plain language rather than testing whether she can repeat clinical terminology.

Turn a handoff into a completed action.

A referral, order or discharge document is the start of a handoff. A completed handoff identifies the receiving clinician, the question to resolve, the current medicines and doses, recent results, pending tasks and the next contact. If no appointment is available, someone needs to address that gap rather than leaving an open-ended instruction to follow up.

Evidence from STRONG H F supports the value of structured, closely monitored care after acute heart failure, but the trial was not restricted to heart failure with preserved ejection fraction. Its exact titration approach should not be transplanted wholesale to every woman with preserved ejection fraction. The transferable lesson here is to design follow-up that actively checks treatment and safety.

For Teresa, the final note should make four things easy to find: what changed, what must be monitored, who will act and when she will hear from the team. At the next contact, confirm the test happened, the result was reviewed and the instruction reached her. The clinical outcome is not an order in the system; it is a patient who knows and can complete the next step.

Here is the decision. The four-week result is missing. Which response best closes the care gap?

Pause here if you would like a moment to think it through.

The best next step in this case is: Check whether testing occurred, resolve access barriers, arrange needed testing and ensure clinician review.

The team needs to track completion as well as interpret results.

The takeaway: Monitoring and coordination are treatment tasks. Pair every medication change with a test date, a responsible reviewer, a communication plan and clear symptom escalation.

Before we move on, let’s apply that reasoning in more detail.

A safety call that cannot wait for the next blood test.

Consider a separate development in Teresa’s story: after starting an S G L T 2 inhibitor she develops vomiting, poor intake, abdominal discomfort and breathlessness. Her home glucose is 146 milligrams per deciliter. This value does not rule out ketoacidosis associated with S G L T 2 treatment. Temporarily stop the medicine and arrange urgent clinical assessment for ketoacidosis, dehydration and other acute illness. Do not use a routine follow-up appointment or reassurance about the glucose value as the response.

For a stable finerenone heart failure candidate with E G F R 42 and potassium 4.7, the current label begins at 10 milligrams daily, after the remaining eligibility and interaction checks. The heart failure target associated with that baseline renal category is 20 milligrams daily, if the follow-up potassium, kidney function and full dose-adjustment instructions support titration. A target is not an instruction to start at the target. For baseline E G F R at least 60, the heart failure starting and target doses differ again.

Do not initiate finerenone with potassium above 5.0 milliequivalents per liter; initiation below E G F R 25 is not recommended. Check contraindications, including strong C Y P 3 A 4 inhibitors and adrenal insufficiency. Use the heart failure-specific table when laboratory values change. A newly prescribed interacting medicine, dehydration, falling blood pressure or an acute illness can make a previously appropriate plan unsafe and may require assessment before the scheduled four-week review.

Close the visit by asking Teresa to show how she will follow the plan: which medicine she is taking, when and where testing will occur, who will contact her, and which symptoms need immediate help. If a laboratory appointment or medication cannot be obtained, make the barrier visible to the responsible team. The plan is incomplete until it is feasible.

Before you go, bring the three cases back to one question: what will you do differently at the next visit?

Explain the symptom, use the endpoint the study actually measured, and give every monitoring plan an owner.

You’ll find the source references, transcript and clinical resources beside this episode. To record your answers and complete the learning activity, return to the activity page for the questions and brief evaluation.

This has been HEART RESERVE Clinical Conversations. I’m Lisa Zahakos. Thank you for listening.